Home / Market News / $MYGN
benzinga Corporate Catalyst Impact 85/100 ● neutral

Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp

Oct 20, 2026, 4:37 PM UTC · Primary ticker $MYGN

Myriad Genetics is divesting its struggling prenatal health testing business to Labcorp for $210 million cash, plus inventory value. This move aims to offload an underperforming segment for Myriad while Labcorp expands its diagnostics portfolio, expecting the acquisition to be accretive to earnings.

Myriad Genetics (MYGN) is selling its prenatal health testing business to Labcorp (LH) for $210 million in cash. This is a significant strategic move for Myriad, as its prenatal unit has been underperforming, with sales declining 16% year-over-year in Q2 2026 and guidance being cut. The divestiture provides Myriad with a cash infusion and allows it to shed a drag on its financial performance, potentially improving its overall profitability and focus. For Labcorp, this acquisition expands its diagnostics segment, adding approximately $160 million in annual revenue and is expected to be slightly accretive to adjusted earnings in the first year. The deal highlights Labcorp's aggressive expansion strategy in specialty testing, as it recently announced another significant acquisition from OPKO Health. Traders should note the immediate positive reaction in MYGN shares due to the removal of an overhang and the cash injection, while LH benefits from strategic growth.

$MYGN positive Divesting underperforming asset, cash infusion
$LH positive Acquiring revenue-generating assets, expanding portfolio
$OPK neutral Mentioned in related Labcorp acquisition, not directly impacted by this deal
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.